(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
latest_posts
- 1
Paul Feig loves a plot twist. Why not reboot 'Die Hard' starring a woman? - 2Jamaica reports deadly leptospirosis outbreak after Hurricane Melissa
- 3The Most Compelling Books of the 10 years
- 4New studies of old dogs help scientists understand where they came from
- 5Nine in 10 German industrial firms expect Iran war to hit business
- In these U.S. groups, deaths now exceed births. What’s happening?
- What do scientists hope to learn from NASA's historic Artemis 2 moon flyby?
- 2 bright planets light up April evenings — here's where and when to look
- Congress is running out of time to extend ACA subsidies as the GOP moves on to an alternative plan. Here's where things stand.
- A hospital discharged a woman in labor. This lawmaker wants change.
- Dick Van Dyke shares his secrets to longevity as he turns 100
- Bitcoin momentum builds in Abu Dhabi as global interest surges
- Iranian missile hit on Ne'ot Hovav factory leads to fear of chemical leakage
- 2024's Savvy Home Gadgets for an Associated Way of life
